Abstract: Objective To evaluate the efficacy and safety of Xianlinggubao capsule in the adjuvant treatment of osteoporosis pain, and provide evidence based reference for clinical treatment. Methods Retrieving CNKI, VIP and Wanfang database, randomized controlled trials（RCT）about Xianlinggubao capsule in the adjuvant treatment of osteoporosis pain were collected. After quanlity evaluation and data extraction,Meta-analysis was conducted by using Rev Man 5.3 statistics software. Results 6 RCTs and a total of 530 patients were included. Results of Meta-analysis indicated that, there was significant difference on the total effective rate [RR=1.27, 95%CI(1.16,1.40), P <0.000 01] and VAS [RR=-1.54, 95%CI(-2.40, -0.68), P <0.05]between 2 groups, there was no significant difference on safety [RR=0.6, 95% CI (0.17, 2.07), P >0.05] between 2 groups.Conclusion The clinical effects of the Xianlinggubao capsule group was better than that of the control group, along with a better pain relief and no more occurrence of adverse reactions. But because this study is a secondary research, the conclusion still remains to be further confirmed.

Key words: Xianlinggubao capsule, osteoporosis pain, Meta-analysis